Investigation Of The Anti-Proliferative Effect Of Synthetic 1-[(Bromomethyl)(phenyl) methyl]-2-(2,4dinitrophenyl)hydrazine Derivative On Cervical Cancer Cells by Othuman, Faiqah Husna Shaik
INVESTIGATION OFTHEANTI-PROLIFERATIVE
EFFECT OF SYNTHETIC 1-[(Bromomethyl)(phenyl)
methyl]-2-(2,4-dinitrophenyl)hydrazine DERIVATIVE
ON CERVICALCANCER CELLS
FAIQAH HUSNA SHAIK OTHUMAN
UNIVERSITI SAINS MALAYSIA
2016
INVESTIGATION OFTHEANTI-PROLIFERATIVE
EFFECT OF SYNTHETIC 1-[(Bromomethyl)(phenyl)
methyl]-2-(2,4-dinitrophenyl)hydrazine DERIVATIVE
ON CERVICALCANCER CELLS
by
FAIQAH HUSNA SHAIK OTHUMAN
Thesis submitted in fulfillment of the requirements
for the degree of
Master of Science
September 2016
ii
ACKNOWLEDGEMENT
I am grateful to the Almighty Allah SWT, who bestowed me the strength, inspiration
and excellent health during the process of completing my studies.
First and foremost, my sincere gratitude to my supervisor, Assoc. Prof. Dr. Md
Azman bin PKM Seeni Mohamed, for providing me the opportunity of this MSc study
with his continuous guidance, assistance, encouragements, and knowledge that helped
me through this process of completing the research. It is an honor and I am very thankful
to have him as my supervisor.
Next, I would like to thank my family for all the supports, advises, and
encouragements in my study, mentally and financially through these years of studies. I
would not have done it without their consistent care.
I would like to express my appreciation to all my friends and lab-mates for their
supports in my study. Especially to Mogana Das, Dr Jahid, Siti Nazmin, and Dr Azlina
for the advises and guidance on lab work and in thesis writing.
Last but not least, I would like to thank to Ministry of Education (MOE) for
awarding MyBrain15 Scholarship to me which truly helped me very much in this study
and not forgetting all IPPT and USM staffs who had helped to complete this study.
iii
TABLE OF CONTENTS
ACKNOWLEDGEMENT ii
TABLE OF CONTENTS iii
LIST OFTABLES viii
LIST OF FIGURES ix
LIST OFABRREVIATIONS xi
ABSTRAK xiii
ABSTRACT xv
CHAPTER 1- INTRODUCTION 1
1.1 Research Background 1
1.2 Hypothesis and objectives 4
CHAPTER 2 - LITERATURE REVIEW 5
2.1 Cervix 5
2.1.1 Anatomy and Physiology 5
2.2 Cancer 7
2.2.1 Epidemiology 7
2.2.2 Cancer Carcinogenesis 8
2.3 Cervical Cancer 10
2.3.1 Risk Factor of Cervical Cancer 11
iv
2.3.2 Symptoms and Staging 12
2.3.3 Treatments for Cervical Cancer 15
2.3.4 Diagnostic tools and tests 18
2.3.5 Prevention of Cervical Cancer 19
2.3.5(a) Vaccination 19
2.4 Cervical Cancer Cell Lines 19
2.5 Hydrazone 20
2.5.1 Background of Hydrazone 20
2.6 Metastasis 23
2.6.1 Overview of Metastasis 23
2.7 Apoptosis 26
2.7.1 Extrinsic pathway (death receptor-mediated pathway) 26
2.7.2 Intrinsic pathway (Mitochondrial pathway) 27
2.8 Cell Cycle 29
CHAPTER 3 - MATERIALSAND METHODS 31
3.1 Reagents, antibodies and kits 31
3.1.1 Reagents for cell culture 31
3.1.2 Reagents for SDS-PAGE and western blot 31
3.1.3 Antibodies for Western Blot 32
3.1.4 Reagents for Invasion Assay 32
3.1.5 Commercial kits 32
3.2 Cell Line 33
3.2.1 Cell Culture 33
v3.2.1(a)The HeLa cell line 33
3.2.1(b) The L929 cell line 33
3.2.2 Subculturing of cells 34
3.2.3 Cryopreservation of cells 34
3.2.4 Resuscitation of frozen cells 35
3.3 Determination of inhibitory concentration (IC50) 36
3.3.1 Calculation of hydrazone compound concentration 36
3.3.2 Treatment of HeLa cells with hydrazone compound in different 36
concentrations.
3.3.3 Trypan blue exclusion assay (TBEA) 38
3.3.4 Microscopic observation of morphological changes 39
3.4 Cell proliferation assay 39
3.5 Apoptosis analysis with flow cytometer 40
3.5.1 Treatment sample preparation 40
3.5.2 Controls preparation for flow cytometer setup 41
3.6 Cell cycle analysis with flow cytometer 42
3.6.1 Treatment sample preparation 42
3.6.2 Preparation of DNAQC Particles for flow cytometer calibration 43
3.7 Protein Extraction 44
3.7.1 Preparation of total cell lysates 44
3.7.2 Determination of Protein Concentration 44
3.7.2(a) Preparation of BSA standards 45
3.7.2(b) Preparation of Protein Samples 45
3.7.2(c) Preparation of Dye Reagent 46
vi
3.7.2(d) Measuring Protein Concentration with Spectrophotometer 46
3.8 Western Blot Analysis 47
3.8.1 Preparation of Reagent 47
3.8.1(a) Running buffer (1xTGS) 47
3.8.1(b) Washing Buffer (1xTG) 47
3.8.1(c) 10%Ammonium Persulfate (APS) 47
3.8.1(d) 10% SDS 47
3.8.1(e) TBS 0.1% Tween20 48
3.8.1(f) TBS 0.3% Tween20 48
3.8.1(g) Blocking Buffer 48
3.8.2 Preparation of Protein Samples for loading 48
3.8.3 SDS-PAGE 49
3.8.4 Semi-dry Blotting of Protein to Nitrocellulose Membrane 50
3.8.5 Blocking of Nitrocellulose Membrane 50
3.8.6 Immunoblotting of Primary and Secondary Antibody 51
3.8.7 Imaging of Membrane 52
3.9 Cell Invasion Assay 52
3.10 Cytotoxicity test with hydrazone compound on L929 cell line 55
3.11 Statistical Analysis 56
CHAPTER 4 - RESULTS 57
4.1 Inhibition concentration (IC50) and morphological changes 57
vii
4.1.1 IC50 of hydrazone compound on HeLa cells 57
4.1.2 Observation on the morphological changes of HeLa cells 59
4.2 Anti-proliferation effect of hydrazone compound on HeLa cells 62
4.3 Apoptotic effect of hydrazonecompound on HeLa cells 64
4.4 Effect of hydrazone compound on cell cycle phase of HeLa cells 67
4.5 Effect of hydrazonecompound on protein expression in cell cycle 70
pathways of HeLa cells.
4.6 Effect of hydrazone compound on invasion of HeLa cells 73
4.7 Cytotoxicity test of hydrazone compound on L929 cells 76
CHAPTER 5 - DISCUSSIONS 79
CHAPTER 6 - CONCLUSION 91
6.1 Conclusion 91
6.2 Limitation and suggestion for future research 92
REFERENCES 93
APPENDICES 106
viii
LIST OFTABLES
Page
Table 2.3 The American Joint Committee on Cancer (AJCC) TNM 14
classification and the International Federation of Gynecology
and Obstetrics (FIGO) staging system for cervical cancer.
Table 3.1 Preparation for BSA standard solutions using 2mg/ml BSA 45
Table 3.2 Preparation of protein samples 46
Table 3.3 Components volume of separating gel per gel volume (~5ml) 50
Table 3.4: Components volume of stacking gel per gel volume (~5ml) 50
Table 4.5 Cells proportions (%) distribution of Annexin V/PI staining 65
Table 4.7 Cell cycle phase distribution (%) 68
ix
LIST OF FIGURES
Page
Figure 2.1 Cross section of uterus and vagina 6
Figure 2.2 The carcinogenesis stages and the occurences involved in 9
each step.
Figure 2.4 The molecular structure of C14H11BrN4O4 compound 22
Figure 2.5 Stages of Metastatic Progression 25
Figure 2.6 Summary of apoptotic signaling pathways as seen through 28
activation of death receptor(extrinsic) or mitochondrial
(intrinsic) pathway.
Figure 3.5 Assembly of western blot semi-dry transblot 51
Figure 3.6 Cell counting field for invasion assay 54
Figure 4.1 Cell Viability of HeLa cells treated with hydrazone 58
compound
Figure 4.2 Light micrograph of HeLa cells with and without hydrazone 60
compound treatment
Figure 4.3 Light micrograph of HeLa cells with hydrazone compound 61
treatment
Figure 4.4 Cell Viability of HeLa cells of cell proliferation assay. 63
Figure 4.6 Annexin V expression for hydrazone compound treatment 66
on HeLa cells.
Figure 4.8 Effect of hydrazone compound on cell cycle of HeLa cells 69
Figure 4.9 Western blot analysis of NF-kB, PCNA, p27kip1, Cyclin E2, 71
Cdc25 and β-actin protein expression in HeLa cells.
Figure 4.10 Effect of hydrazone compound on protein expression 72
in cell cycle of HeLa cells.
Figure 4.11 Light micrograph of Invasion assay 74
xFigure 4.12 Effect of hydrazone compound on HeLa cells through 75
Invasion assay
Figure 4.13 Light micrograph of L929 cells 77
Figure 4.14 Effect of hydrazone compound on L929 cell line 78
Figure 5.1 Suggested pathway induced by hydrazone compound 87
treatment leading to cell cycle arrest in HeLa
xi
LIST OFABBREVATIONS
0C Degree celcius
% Percentage
g Gram
g/mL Gram per milliliter
mg/mL Milligram per milliliter
mL Milliliter
μg Microgram
μg/mL Microgram per millimeter
μL Microliter
APS Ammonium Persulfate
ATCC American Type Cell Culture
BSA Bovine SerumAlbumin
Cdc Cell division cycle protein
CDK Cyclin dependent kinase
CEN Chicken erythrocyte nuclei
CIN Cervical Intra Neoplasia
CO2 Carbon Dioxide
CTN Calf thymocyte nuclei
DNA Deoxyribonucleic acid
DMEM Dulbecco’s Minimum Essential Medium
DMSO Dimethyl sulfoxide
EDTA Ethylenediaminetetraacetic acid
xii
FBS Fetal Bovine Serum
FITC Fluorescein isothiocyanate
HPV Human Papillomavirus
PBS Phosphate Buffered Saline
PI Propidium iodide
RIPA Radioimmunoprecipitation assay
rpm Revolution Per Minute
SD Standard Deviation
SDS Sodium dodecyl sulfate
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
TBEA Trypan Blue Exclusion Assay
TBS Tris Buffer Saline
TEMED tetramethylethylenediamine
xiii
PENYIASATAN KESAN ANTI-PROLIFERATIF SINTETIK 1 - [( Bromomethyl )
( phenyl )methyl ] -2- (2,4- dinitrophenyl ) HIDRAZIN DERIVATIF PADA
SEL-SEL KANSER PANGKAL RAHIM
ABSTRAK
Kanser pangkal rahim masih kekal sebagai kanser yang kedua tertinggi di
kalangan wanita dan punca ketiga utama kematian walaupun pelbagai rawatan sedia ada.
Kurang keberkesanan rawatan tersebut telah menyebabkan para saintis mencari rawatan
alternatif bagi penyakit ini. Strategi agen anti-proliferatif baru untuk kanser pangkal
rahim adalah salah satu inovasi yang penting dalam melawan penyakit yang sengsara ini.
Walaupun derivatif hydrazone sintetik telah digunakan secara meluas dalam
penyelidikan kanser tetapi mekanisme anti-kanser yang sebenarnya yang ditunjukkan
oleh bahan kimia ini masih belum diketahui. Kajian ini cuba menjelaskan kesan-kesan
anti-proliferatif1 - [( Bromomethyl ) ( phenyl ) methyl ] -2- (2,4- dinitrophenyl ) hidrazin
(C14H11BrN4O4) derivatif (kompaun Hydrazone) pada sel-sel kanser pangkal rahim
melalui penentuan kepekatan perencatan (IC50), assay anti- proliferatif, assay apoptosis,
assay kitaran sel, analisis Western Blot, assay invasi dan analisis cytotoxicity .Hasil
kajian menunjukkan dos IC50 bagi kompaun Hydrazone adalah 0.03mg/ml pada sel-sel
kanser pangkal rahim dan berjaya menghalang proliferasi sel-sel kanser berbanding
dengan sel-sel kanser yang tidak dirawat. Di samping itu, aliran sitometri analisis
mengesahkan hydrazone derivatif menyebabkan pembantutan sintesis deoxyribonucleic
acid (DNA) pada fasa S dan G2 / M tanpa induksi apoptosis. Analisa ‘ western blot’
menunjukkan peningkatan ekspresi protein p27kip1 dan PCNA serta merencatkan
ekspresi protein Cyclin E2 dan cdc25. Kesan anti-metastasis dikaji melalui analisis
xiv
invasi dan ia menunjukkan kompaun hydrazone telah menghalang 50.94 % invasi sel
HeLa. Kesimpulannya kompaun hydrazone memiliki kesan anti-proliferatif pada sel
HeLa.
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INVESTIGATION OFTHEANTI-PROLIFERATIVE EFFECT OF SYNTHETIC
1-[(Bromomethyl)(phenyl) methyl]-2-(2,4-dinitrophenyl)hydrazine DERIVATIVE ON
CERVICALCANCER CELLS
ABSTRACT
Cervical cancer remains as the second most common type of cancer in women and it
is the third leading cause of death despite various treatments that are available.
Inefficiency of present treatments had triggered scientists to seek for an alternative
treatment for this disease. Development of new anti-proliferative agent for cervical
cancer is an important innovation in fighting this miserable disease. Although, synthetic
hydrazone derivatives are widely being used in cancer research, the actual anticancer
mechanism shown by these chemicals is still not yet understood. Therefore this study
aimed to elucidate the anti-proliferative effects of the 1-[(Bromomethyl)(phenyl)methyl]
-2-(2,4 -dinitrophenyl) hydrazine (C14H11BrN4O4) derivative (Hydrazone compound) on
cervical cancer cells through determination of inhibitory concentration (IC50),
anti-proliferative assay, apoptosis assay, cell cycle assay, western blot analysis, invasion
assay and cytotoxicity analysis. The results showed the IC50 of the hydrazone compound
at 0.03mg/ml on the cervical cancer cells and inhibits the proliferation of cervical cancer
cells in a dose and time-dependent manner compared to the untreated control. In addition,
the flow cytometry analysis confirmed the hydrazone derivative causes S and G2/M
phase cell cycle arrest without induction of apoptosis. Western blot analysis showed that
hydrazone compound had increased the p27kip1 and PCNA and suppressed Cyclin E2 and
cdc25 protein expression. The anti-metastatic effect was studied through invasion assay
and it showed the hydrazone compound had inhibited 50.94% of HeLa cells invasion. It
xvi
is concluded the hydrazone compound possesses anti-proliferative effect on HeLa cells.
1CHAPTER 1
INTRODUCTION
1.1 Research Background
Cancer is a disease that has been discovered since 1500 BC by the Egyptians.
The term was introduced by the Greek physician Hippocrates who called it as
karkinos, which means crab (Hasan, 2009). Nowadays this disease is been one of
the dominating cause of death in developed and non-developed countries (Torre et
al., 2015). Cancer able to arise almost in all human organs. The incidence of cancer
and death is on a rising from year to year worldwide.
Cervical cancer was one of the most common cancer among women with an
estimated incidence of 527, 600 cases and 265, 700 deaths worldwide in the year
2012 (Torre et al.,2015). While the National Cancer Registry (NCR) had stated in
the year 2007, cervical cancer is been in third rank, with a total of 847 cases
diagnosed in Malaysia (Omar and Tamin, 2011). In the year 1943, Pap Smear was
developed and since then it has been widely used for the screening of cervical
cancer. This test had helped in the reduction of cervical cancer mortality by 70% in
the period of 50 years in the US (Almeida & Barry, 2008). Human papillomavirus
(HPV) are believed to be strongly related to cervical cancer. This virus used to be
one of the main risk factors in this type of cancer and there is more than 200 types
of viruses discovered (American Cancer Society, 2015). It is believed that the
introduction of the (HPV) vaccine had reduced the incidence of this cancer in most
of the developed countries(Lowy & Schiller, 2012).
2The diagnostics tools of cervical cancer such as Pap smear and HPV test help to
reduce the incidence of this cancer. Furthermore the early detection of this cancer
may assist in the identification and selection of treatment to work more efficiently.
Nevertheless, there is the necessity for an introduction of better alternative treatment
to improvise the prognosis and mortality rate of this disease. Hence, new treatment
approaches are required to inhibit the progression of cervical neoplasia before it
undergo metastasis.
The approach of finding new treatments for cancer is not only restricted to
naturally available resources but synthesized chemicals are also being widely
practiced. One of the versatile compounds is hydrazone. The hydrazone derivatives
are not only play the role as anti-inflammatory, anti-microbial, anti-HIV but also
believed to have anti-cancer properties (Belskaya et al., 2010; Rollas & Kucukguzel,
2007). Previous studies had showed tremendous results of hydrazone derivatives
treatments on cancer (Gursoy and Karali 2003; Terzioglu and Gursoy 2003; Zhang
et al., 2004; Gursoy and Guzeldemirci-Ulusoy, 2007). In this study
1-[(Bromomethyl)(phenyl)methyl]-2-(2,4 -dinitrophenyl) hydrazine (C14H11BrN4O4)
derivative (hydrazone compound) was chosen to act as a treatment to halt the
proliferation process. This hydrazone compound had been used to treat tongue
cancer cells and shown to act as apoptotic inducer with addition of chemopreventive
activity (Zulkepli et al.,2011).
Other than that, another prospect of this study is to determine the anti-metastatic
effect of hydrazone compound on cervical cancer cells. Once the cancer undergo
3metastasis, it is unlikely to find a cure for this disease and often would lead to death.
There were few previous studies that introduced drugs and anti-metastatic agents on
cervical cancer (Park et al., 2010; Liu et al., 2012; Onal et al., 2013; Henderson et
al., 2015; Buyukkarabacak et al.,2015). Somehow the search for the prevention of
metastatic cancer is still not achieved. Thus, there is a requirement for the search of
preventive agent on metastasis of cervical cancer. This study had researched the
ability of hydrazone compound to suppress the invasion process of HeLa cells.
Somehow the overall progression in cervical cancer showed no dramatic
changes even after the presence of few diagnostic, screening and treatments for this
cancer (Takekuma et al., 2015). This study offers an understanding on the
anti-proliferative effect of the hydrazone compound on cervical cancer cell line.
41.2 Hypothesis and objectives
The hypothesis of this study is that the hydrazone compound induces apoptosis
and act as anti-proliferative agent.
The general objective of this study is to learn the chemoprevention effect and
anti-proliferative effect of hydrazone compound on cervical cancer cells (HeLa
cells). Apart from that, specific objectives of this research include :
1) To determine the inhibitory concentration (IC50) of synthetic hydrazone
compound in cervical cancer cells.
2) To identify anti-proliferative effect of synthetic hydrazone compound in cervical
cancer cells.
3) To investigate the effect of synthetic hydrazone compound on the apoptosis of
cervical cancer cells.
4) To investigate the effect of synthetic hydrazone compound on the cell cycle
pathway of cervical cancer cells.
5) To investigate the antimetastatic effect of synthetic hydrazone compound in
cervical cancer cells.
The experimental design of this study is shown in a flow chart in APPENDIX A.
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LITERATURE REVIEW
2.1 Cervix
2.1.1 Anatomy and Physiology
The female reproductive system consists of internal organs such as uterus,
ovaries, vagina and external organs which include the vulva. Cervix is one of the
organ of the female reproductive system which is the lower fibromuscular part of
the uterus, conical or cylindrical in structure (Tortora, 2009). According to Spencer
(2007), the term cervix originates from the Latin word “neck”, since it is long and
cylindrical in structure. The cervical tissue connects the uterus with the vagina.
Cervix can be divided into two parts, endocervix and ectocervix. The endocervix is
the region nearer to the uterus opening and the ectocervix is the part that extends
toward the vagina. The endocervix consists of columnar cells which are actually
glandular cells that synthesize mucus. While the ectocervix is lined with stratified
squamous cells and these cells were consist of multiple layers which are parabasal,
basal, intermediate and superficial layer. The cells of endocervix and ectocervix
joins to form a squamo-columnar region. The overlapping region is known as the
transformation zone (Tortora, 2009). Columnar cells at the transformation zone
undergo changes into squamous cells and this region is vulgar to the development of
abnormal cells. According to Wylie (2005), columnar epithelium which presents
along the cervix secretes mucus in order to synthesize a protective plug against any
infection in the internal genitalia. Furthermore, the transformation zone varies
6among women throughout their lifetime. Commonly, the transformation zone in
teenagers will be on the outer surface of cervix and it is more prone to get infections.
While on other hand, the transformation zone will be on the canal of cervix in older
women. Human cervix tend to dilate during menstrual flow and dilate widely during
childbirth. The cervix can be in various sizes and structures depending on the age of
women, hormonal status and parity (Tortora, 2009).
Figure 2.1 : Cross section of uterus and vagina. Adapted from Moore and Agur,
2007.
72.2 Cancer
2.2.1 Epidemology
Cancer is a disease that leads to the uncontrolled mitotic cell division. Cancer
can arise from any part of the human body. The normal cells of human usually
undergo cell division in a programmed manner and when become old or damaged,
the cells will die and replaced with new cells. If cancer develops, the cells will be
abnormal and the growth will be in faster rate compared to the normal cells.
Furthermore, the cancer cells do not undergo programmed cell death. Cancer cells
keep dividing and form tumor. There are two types of tumor, benign and malignant.
According to Almeida and Barry (2010), benign tumor does not spread to nearby
tissue, has a well defined perimeter and somehow will only be dangerous if the
tumor compress surrounding tissues. On the other hand, malignant tumor is able to
metastasize to nearby tissues through lymphatic system, blood vessels and even
through infected tissues (Dong et al, 2009).
Cancer remains as the deadliest disease in the world until today. The incidence
of cancer is increasing due to the aging and growth of the population, overweight,
smoking, physical inactivity and changing of reproductive patterns (Torre et al,
2015). In the year 2014, the number of people who had been diagnosed with cancer
reached almost 14.5 million and it is estimated to increase to 19 million by the year
2024 (National Cancer Institute, 2015). Lung, breast and colorectal cancers are in
the highest rank as the main cause of cancer death in more and less developed
countries (Torre et al,2015).
82.2.2 Cancer Carcinogenesis
Multiple steps are involved in the development of cancer from a normal cells.
This process of transformation is known as carcinogenesis. The carcinogenesis
involves three stages, which include initiation, promotion, and progression
(Hennings et al., 1993). The experiments which have been done using the animal
models showed similar carcinogenesis process in human, somehow due to exposure
to various chemical compounds by the human throughout their life do alter the
speed of the process and result in different effect (Oliviera et al., 2007). Figure 2.2
illustrate the processes of the carcinogenesis, including the three stages that are
involved.
Initiation is the first stage of carcinogenesis where the damaged genetic material
(DNA or RNA) results in unregulated growth of cells. The initiation stage is
reversible and involves both intracellular factors such as inflammation, oxidative
stress, inherited genes and hormone, and extracellular factors like exposure to
carcinogens, life style and diet (Bertram, 2001). The second stage is the promotion
process where a malignant cell is able to reproduce itself and multiply to give rise to
large malignant cell numbers. The last stage is the progression which imply growth
and expansion of the cells of tumor with potency of metastasis. In the initiation and
promotion stage, the cell proliferation and apoptosis take place in different rates but
managed to be balanced, but in the progression stage both of the mechanisms are
altered and may lead to uncontrolled mitosis (Mehta, 1995).
9Figure 2.2 : The carcinogenesis stages and the occurences involved in each step.
Adapted from Oliviera et al., 2007.
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2.3 Cervical cancer
Cervical cancer is a slow progressing cancer in the cervix of female
reproductive system. This type of cancer does not show an obvious symptoms at the
early stage and it begins with a precancerous condition which is known by a few
terms such as dysplasia, cervical intraepthelial neoplasia (CIN), and squamous
intraepthelial lesion (SIL) (American Cancer Society, 2015). The abnormality
growth usually starts in the transformation zone of the cervix. The classification of
precancerous and cancerous of the cervix is based on the morphology observed
under microscope.
Squamous cell carcinoma and adenocarcinoma are the most periodically
diagnosed type of cervical cancer. The squamous cell carcinoma originates in the
squamous cells of the cervix, which is the ectocervix region. While the
adenocarcinomas begin in the endocervix part. It develops in the gland cells which
is responsible to produce mucus. Furthermore, some of the cervical cancers have
features of both, adenocarcinomas and squamous cell carcinomas. These type of
cancer is known as adenosquamous carcinomas or mixed carcinomas (American
Cancer Society, 2015).
Cervical cancer had been in the top three rank in the cancer statistical list. New
cases of 11,000 and 4,000 deaths of cervical cancer had been estimated by the
American Cancer Society in the year 2008 (Almeida & Barry, 2010). Cervical
cancer is in the second rank as the most diagnosed cancer and the third leading
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cause of death especially in less developed countries (Torre et al, 2015). In less
developed countries, the importance and the knowledge on the presence of the
screening test and the vaccination of HPV is lacking. In Asia, 144,400 deaths due to
cervical cancer has been reported in the 2012 (Torre et al, 2015). In Malaysia
cervical cancer was the third most common cancer in women with 847 cases been
diagnosed in the year 2007 (Omar & Tamin, 2011).
2.3.1 Risk Factors for Cervical Cancer
A few risk factors can lead to an increase in the development of cervical cancer
in women. These factors include infections with Human Papillomavirus (HPV),
smoking, immunosuppression, overweight and others. In most of the cervical cancer
cases HPV infection used to be the main risk factor. HPV are non-enveloped virus
with double stranded DNA in circular structure with 8,000 base pairs (Gillison,
2008). There are two higher-order genera, α-papillomaviruses which attack the
mucosal epithelia and β-papillomaviruses infect cutaneous epithelia (De Villiers et
al., 2004). The papillomaviruses are basically categorized as ‘high-risk’,
‘moderate-risk’ and ‘low-risk’. The α-papillomaviruses have clearly established as
carcinogenic for human (Gillison, 2008).
Smoking is not only one of the major risk factors for cervical cancer but also for
all types of cancer. The substances present in the cigarette are harmful and women
who smoke are incline to get cervical cancer. Researchers believe that the materials
in the cigarette are responsible in destroying the DNA of cervical cells. In addition,
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the immune system of a smoker will be less efficient in combating the infections of
HPV.
Immune system is plays a very important role in combating the cancer cells.
Women who suffer from autoimmune diseases, AIDS and had organ transplant are at
higher risk for HPV infections compared to healthy person. Since this group of
people have weak immunity toward diseases, they are more easily exposed to cancer.
Women who consumes birth control pills for a long period of time increases the risk
of cervical cancer. According to the researchers the risk of cervical cancer increases
in women who use oral contraceptives. Somehow the risk decreases once they
stopped consuming it. Other than that, women who are exposed to diethylstilbestrol
(DES) are likely to develop clear-cell adenocarcinoma. Daughters who had their
mothers took DES during pregnancy are also at risk of getting precancerous and
squamous cell cancers of the cervix. Furthermore, women who have family history
of cervical cancer may have chances to develop the cancer (Colditz & Stein, 2004;
Almeida & Barry, 2010; American Cancer Society, 2015).
2.3.2 Symptoms and Staging
Women who developed the precancerous or early cervical cancer usually do not
have any specific symptoms. The symptoms only present once the cancer turned out
to be invasive and starts to spread to nearby tissues. Most common symptoms
include unusual discharge of the vagina, pain while having intercourse, pelvic pain
and abnormal bleeding of vagina (Almeida & Barry, 2010). Since the symptoms are
normally correlated with female reproductive tract diseases, further examinations
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and physician consultancy are necessary.
In most cases of cervical dysplasia there are possibility of cure without
treatment, however early detection promised better treatment to overcome this type
of cancer. If the abnormal cells are left untreated, there is a high possibility that it
become malignant (Braun & Anderson,2007). The staging of cervical cancer is
based on the size of tumor and the spreading of the cancer cells to other parts of
body. The International Federation of Gynecology and Obstetrics (FIGO) has
clinically defined cervical cancer (Table 2.3).
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Primary tumor (T)
TNM FIGO Surgical-Pathologic Findings
Categ
ories Stages
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ (preinvasive carcinoma)
T1 I Cervical carcinoma confined to the cervix (disregard extension to the corpus)
T1a IA
Invasive carcinoma diagnosed only by microscopy; stromal invasion with a maximum depth
of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or
less; vascular space involvement, venous or lymphatic, does not affect classification
T1a1 IA1 Measured stromal invasion ≤ 3.0 mm in depth and ≤ 7.0 mm in horizontal spread
T1a2 IA2 Measured stromal invasion > 3.0 mm and ≤ 5.0 mm with a horizontal spread ≤ 7.0 mm
T1b IB Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2
T1b1 IB1 Clinically visible lesion ≤ 4.0 cm in greatest dimension
T1b2 IB2 Clinically visible lesion > 4.0 cm in greatest dimension
T2 II Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina
T2a IIA Tumor without parametrial invasion
T2a1 IIA1 Clinically visible lesion ≤ 4.0 cm in greatest dimension
T2a2 IIA2 Clinically visible lesion > 4.0 cm in greatest dimension
T2b IIB Tumor with parametrial invasion
T3 III Tumor extends to pelvic wall and/or involves lower third of vagina and/or causeshydronephrosis or nonfunctional kidney
T3a IIIA Tumor involves lower third of vagina, no extension to pelvic wall
T3b IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctional kidney
T4 IV Tumor invades mucosa of bladder or rectum and/or extends beyond true pelvis (bullousedema is not sufficient to classify a tumor as T4)
T4a IVA Tumor invades mucosa of bladder or rectum (bullous edema is not sufficient to classify atumor as T4)
T4b IVB Tumor extends beyond true pelvis
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis (including peritoneal spread; involvement of supraclavicular, mediastinal, orpara-aortic lymph nodes; and lung, liver, or bone)
Table 2.3 : The American Joint Committee on Cancer (AJCC) TNM classification and
the International Federation of Gynecology and Obstetrics (FIGO) staging system for
cervical cancer.
15
2.3.3 Treatments for Cervical Cancer
The progression of cervical cancer is very slow, it usually takes few years to
develop cancer from a precancerous condition. Somehow the development of cancer
can even occur in less than one year. The precancerous condition is able to disappear
without any treatment in most women. Treatment of precancerous cells of the cervix
can prevent the occurrence of cervical cancer. Treatments that are available for
cervical cancer include surgery, chemotherapy, radiotherapy and targeted-therapy.
The first choice of treatment for cervical cancer is the surgery. A few types of
surgeries are recommendable for this cancer which include cryosurgery, laser
surgery, conisation, hysterectomy, radical hysterectomy, trachelectomy, pelvic
exenteration and pelvic lymph node dissection (Jeevan & Olah, 2015).
Cryosurgery is a method of placing a metal probe which is cooled using liquid
nitrogen directly on the cervix to kill the abnormal cells. It is normally performed to
treat carcinoma at stage 0, which is not invasive (Basta et al, 2015). Laser surgery is
performed using a laser beam which is focused through the vagina to vaporize
abnormal cells or to discard a small part of tissue for study purpose. Furthermore,
the laser surgery is also been used to treat carcinoma of stage 0. The next one will be
the conization, where a piece of cone structured tissue is isolated from cervix using
a laser knife or with a thin wire that heated with electricity (the loop electrosurgical,
LEEP procedure). The cone tissue biopsy might be used for diagnostic purpose
before proceeding with additional treatments. This treatment may also be performed
in patient with an early stage of cervical cancer (American Cancer Society, 2015).
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Hysterectomy is a surgical removal of the uterus and the cervix. If the removal
is done through the surgical incision of the abdomen, then the surgery is known as
abdominal hysterectomy, if removed through vaginal it is known as vaginal
hysterectomy and if it is through laparoscopy, it is known as laparoscopic
hysterectomy. Other than that, there is also radical hysterectomy which removes the
uterus including the nearby tissues including upper part of the vagina. The
procedure is preformed through abdominal incision and usually pelvic lymph nodes
will be removed. This type of surgery is normally conducted for the treatment of
stage IA2, IB and IIA of cervical cancer. Furthermore, there is another type of
hysterectomy, radical trachelectomy, which treat stage IA2 and IB cervical cancer
and grant women the ability to get pregnant even after treatment. The procedure
involves isolation of the cervix and vagina without removing the uterus (Musaev et
al. 2015).
Pelvic exenteration and pelvic lymph node dissection are surgery which is
conducted for cancer which had spread. In pelvic exenteration procedure, not only
the uterus region will be removed, but vagina, bladder, rectum even a part of the
colon might be removed, based on the spreading of the cancer. During the pelvic
lymph node dissection, surgeon may isolate some lymph nodes to verify the stage of
the cancer (Pomel et al, 2003).
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The following type of treatment will be the radiation therapy. High energy
particles or x-rays is used to kill the cancer cells (Li et al, 2015). The therapy can be
done externally or internally. External beam radiation therapy (EBRT) involves
x-rays beam directed to the cancer from outside of the patient body. The radiation
dose is stronger and the treatment is painless. Unfortunately, the treatment may give
side effects to the patient. Normally the EBRT procedure will be followed by
chemotherapy, therefore the therapy is simultaneously called as chemoradiation.
The other type of radiation therapy which is internally practiced is brachytherapy
where the radiation source is placed in or adjacent to the cancer. In cervical cancer,
intracavitary brachytherapy procedure is performed by placing the source of
radiation through a device which is in the vagina or even in the cervix (American
Cancer Society, 2015).
The next type of treatment for cervical cancer is chemotherapy, where
anti-cancer drugs are injected through the vein or consumed by mouth. These drugs
will be introduced to the bloodstream and delivered to all body parts, which then
acts on the cancer cells in the entire patient’s body. Usually chemotherapy is given
in cycles manner which gives a certain period of time for recovery of the patient.
Chemotherapy is used in treating cancer which had spread to other parts of the body.
There are a few drugs which have been frequently used to treat advanced cancer of
cervix including cisplatin, topotecan, carboplatin, paclitaxel and gemcitabine
(American Cancer Society, 2015).
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Nowadays, due to better understanding on the characteristics of cancer cells and
researchers have successfully developed few new drugs which act as targeted cancer
treatments. Angiogenesis is the synthesis of new blood vessels and cancer do
undergoes metastasis through the help of this process. Angiogenesis inhibitor can be
used as a target therapy to immobilize the growth of new blood vessels. In the case
of cervical cancer, bevacizumab which is an angiogenesis inhibitor, target the
vascular endothelial growth factor (VEGF) that assist in new blood vessels
formation (American Cancer Society, 2015). Furthermore, according to American
Cancer Society (2016) the addition of targeted therapy in women who are taking
standard chemotheraphy treatment had helped to improve the overall survival rate.
2.3.4 Diagnostic tools and tests
Nowadays there are a few screening tests available for an early detection of
cervical cancer. The presence of HPV can be analyzed with Pap smear, biopsy, DNA
hybridization and Polymerase Chain Reaction (PCR) amplification (Borutto &
Comparetto, 2012). Pap smear turns out to be one of the effective test for the
detection of cervical cancer during early stage and this tests is available in most
hospitals. Currently there are two type of HPV test present, the HPV DNA test
which is able to identify 13 types of HPV which are in the category of high-risk and
the HPV PCR test which is also used in few hospitals and laboratories (Almeida &
Barry, 2010).
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2.3.5 Prevention of Cervical Cancer
2.3.5(a) Vaccination
Cervical cancer is a disease which can be completely cured if the abnormal cells
were detected at early stage. The presence of diagnostic tools and tests ease the
treatment of this cancer. Complementary to this is the discovery of HPV vaccines
that give a great promise to decrease the incidence of cervical cancer. Generally
preventive vaccine work by neutralizing antibodies toward HPV infections. Two
types of vaccines have been introduced for the preventive purpose, ‘Gardasil’ and
‘Cervarix’. Gardasil is a vaccine which targets four types of HPV, which are
HPV-16,-18,-6, and -11. HPV types 16 and 18 are observed approximately in
70-75% of cervical cancer, while HPV types 6 and 11 lead to nearly 90% of genital
warts. The length of protection of this vaccine is up to 5 years. Cervarix consists of
HPV types 16 and 18, which also gives protection for 5 years (Roden et al, 2008).
2.4 Cervical Cancer Cell Lines
There are different types of cervical cancer cell lines can be used in research,
which include HeLa, SiHa, CaSki, C33A and DoTc2. Each of the cell lines has
different origin, characteristics and capability as reported by the ATCCR (American
Type Culture Collection) CCL-2TM product sheet. Some are very well established
and have been used for years in the research field. C33A cell line exhibited a
hypodiploid karyotype intially and epithelial morphology. The cells are negative for
HPV DNA and RNA. CaSki cells are derived from metastatic site in the small bowel
mesentery and contain HPV type 16 and sequence related to HPV-18. SiHa cells are
adherent epithelial cells obtained after surgery from a Japanese patient and is a
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suitable host for transfection. HeLa cells are adherent adenocarcinoma cells that are
suitable transfection host. HeLa cell is one of the very well established cells in the
research field and has successfully been used in few experiments such as polio
vaccine development, viruses growth studies, study of cancer causes and cure for
leukemia (Almeida & Barry, 2011).
The HeLa cells were isolated from a cervical cancer patient named Henrietta
Lacks in the year 1951 (Spencer, 2009). The cells were named after her first two
letters of her first and last name. HeLa cell is the first human cell which successfully
grow in the in vitro condition. The malignant cells were obtained from her cervix
through a quarter sized tumor, where by that time the cancer already spread to most
of her body parts (Almeida & Barry, 2011). The cells are adherent cells of the cervix
epithelial adenocarcinoma. A report by the ATCCR (American Type Culture
Collection) CCL-2TM product sheet, the cells contain HPV-18 strain. The cells are
being used widely in research and the cells keep multiply aggressively until today.
2.5 Hydrazone
2.5.1 Background of Hydrazone compound
A lot of different treatments have been used in the new search of cure for cancer.
There are naturally present sources and synthesized chemicals widely used as the
treatments. One of the synthesized chemicals which has potency to act as an
anti-cancer treatment is the hydrazone. There are varieties of chemically synthesized
hydrazone derivatives, depending on the functional group attached. Basically
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hydrazones have two bonded nitrogen atoms with different nature with a C-N
double bond that is conjugated with a single electron pair at the nitrogen terminal
(Belskaya et al, 2010). Moreover, according to Belskaya et al (2010) hydrazones are
easily prepared, have tendency toward crystallinity and increased hydrolytic
stability compared to imines and these are the main positive traits which encourage
to learn more about this compound.
Hydrazones exhibit physiological activities when used as a treatment in several
diseases (Monfared et al, 2007). Furthermore, Rollas and Kucukguzel (2007) stated
that hydrazone derivative is one of crucial class of chemicals which poses
anti-cancer properties. Previous studies had shown the anti-cancer effects of
different hydrazone derivatives, such as 3-[[(6-chloro-3-phenyl-4(3H)-
quinazolinone-2-yl) mercaptoacetyl] hydrazono]-5-fluoro-1H-2-indolinone which
demonstrated cytotoxicity effects on renal cancer cell line (Gursoy and Karali 2003),
(2,6-dimethyl-N-(2-hydroxyphenyl-methylidene)imidazo[2,1-b][1,3,4]thiadiazole-5-
carbohydrazide showed effects on cancer cells of the ovary (Terzioglu and Gursoy,
2003) and 5-chloro-3-phenylindole-2-carboxylicacid(4-nitrobenzylidene) hydrazide
which proven to inhibit the growth of breast cancer cells (Zhang et al., 2004).
One of the hydrazone derivatives is the 1-[(Bromomethyl)(phenyl)methyl]-2-
(2,4-dinitrophenyl) hydrazine (C14H11BrN4O4), which consists of two crystallo-
graphically independent molecules which are in the asymmetric unit (Salhin et
al,2009). This hydrazone compound have been previously used to treat tongue
cancer cell line and proven to act as a potential chemopreventive agent (Zulkepli et
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al.,2011). This hydrazone compound had been chosen in this study to investigate its
potential and anti-metastatic properties against cervical cancer in vitro.
Figure 2.4 : The molecular structure of the hydrazone compound. Adapted
from Salhin et. al, 2009.
23
2.6 Metastasis
2.6.1 Overview of Metastasis
The term metastasis refers to the dissemination of cancer cells from the
primary tumor to other parts of the body. Metastasis remains as one of the main
contributors towards mortality and morbidity of cancer cases (Pienta et al, 2013).
According to Gupta and Massague (2006), for centuries cancer biologists believed
that metastasis process resulted from the interactions of tumor cells with the
permissive target tissues. The cancer cells which undergo metastasis will look
similar as the original or the primary cancer when observed under microscope
(Dong et al, 2009). Furthermore, the molecular characteristics between the
metastatic cancer cells and the original cancer cells are usually similar, such as the
presence of particular chromosomal changes and expression of specific proteins
(National Cancer Institute, 2013). Cancer which is formed through these processes
are known as metastatic cancer and the tumor is called metastatic tumor.
Metastasis process starts in the last stage of tumorigenesis (Lim et al, 2004).
According to National Cancer Institute (2013) basically there are series of processes
involved in cancer cell metastasis which includes local invasion, intravasation,
circulation, arrest and extravasation, proliferation and angiogenesis. Cell motility
plays a key role in the progression of cancer to become invasive and undergo
metastasis (Lang et al, 2005). The cancer cells start to into on surrounding tissues
and travel to different region of the body with the help of the bloodstream and
lymphatic system. When the cells are arrested or stop moving when reached the
blood capillaries, they intrude on the capillaries wall and travel to nearby tissues.
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Cancer cells starts to proliferate at distant location to form micrometastases. Later
there will be angiogenesis process which is the synthesis of new blood vessels as the
source of obtaining necessary needs such as oxygen and nutrients by the cancer cells
to continue growing. Treatments are available for all patients with metastatic
cancers, unfortunately most of the metastatic cancers cannot be cured with the
present treatments. The main purpose of metastatic cancer treatment is to stop the
spreading of the cancer from primary tumor to other parts of body. Furthermore,
metastasis is one of the major reasons for the death of cancer patients (National
Cancer Institute, 2013).
Better understanding on the molecular sequence in various stages of metastasis
will help to identify the target of therapies (Dong et al., 2009). Malignant cancers
always have higher affinity to undergo metastasis process. This includes cervical
cancer which is one of the threat for women worldwide and previous studies had
discussed the possibilities of treatments for the cervical metastasis (Lim et al., 2004;
Yuan et al., 2008; Rah et al., 2012; Song et al., 2013; Li et al., 2014).
